Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7238 results

Sort By:

Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors

Study ID: NCT05733091
Start Date: 2018-12-20
End Date: 2029-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

Standard of Care

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Study ID: NCT06860594
Start Date: 2026-03-01
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

30

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Intensity-Modulated Radiation Therapy

Magnetic Resonance Imaging

Triapine

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES

Study ID: NCT05628194
Start Date: 2023-06-08
End Date: 2026-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

5000

Intervention / Treatment

Observational/Survery

Sponsor

University of Minnesota

Source: clinicaltrials.gov

Share:
Add to list

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Study ID: NCT05166694
Start Date: 2022-11-30
End Date: 2027-11-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1300

Intervention / Treatment

Drug-Drug Interaction Profile

Drug-Gene Interaction Profile

Standard of Care

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Study ID: NCT06634394
Start Date: 2024-10-01
End Date: 2028-03
Study Type

Interventional

Study Phase

Phase1

No. of Participants

39

Intervention / Treatment

APVO436

Venetoclax

Azacitidine

Sponsor

Aptevo Therapeutics

Source: clinicaltrials.gov

Share:
Add to list

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Study ID: NCT05600894
Start Date: 2023-06-27
End Date: 2025-08-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Venetoclax

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Study ID: NCT02474160
Start Date: 2015-05-19
End Date: 2026-05-04
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

5000

Intervention / Treatment

Cytology Specimen Collection Procedure

Sponsor

National Cancer Institute LAO

Source: clinicaltrials.gov

Share:
Add to list

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Study ID: NCT03463460
Start Date: 2018-06-19
End Date: 2025-07-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Laboratory Biomarker Analysis

Pembrolizumab

Sunitinib Malate

Sponsor

Dwight Owen

Source: clinicaltrials.gov

Share:
Add to list

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Study ID: NCT06323460
Start Date: 2024-03-21
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Biospecimen Collection

Carboplatin

Cisplatin

Computed Tomography

External Beam Radiation Therapy

Paclitaxel

Positron Emission Tomography

Administration questionnaire

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Study ID: NCT05360160
Start Date: 2022-10-14
End Date: 2026-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

43

Intervention / Treatment

SNDX-5613

Venetoclax

ASTX727

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list